« Return to News | R&D Trends

Heidelberg Pharma, Roche ink license agreement

Wednesday, September 4, 2013 03:57 PM

Germany-based Heidelberg Pharma, a wholly owned subsidiary of Wilex, has signed a license agreement with Roche covering the development of a novel class of antibody drug conjugates (ADCs) based on Heidelberg Pharma’s patented technology to couple α-Amanitin to antibodies. The license agreement covers initial joint research to apply this technology to multiple Roche antibodies towards the identification of development candidates with favorable efficacy/safety profiles.

Heidelberg Pharma will receive regular payments for granting access to its technology and providing research services. Roche will subsequently have the opportunity to exercise options for licenses to develop and market selected Antibody Targeted Amanitin Conjugates (ATACs). Heidelberg Pharma will manufacture these substances and receive customary upfront payments, milestone payments and royalties for each development candidate selected by Roche.

Dr. Jan Schmidt-Brand, managing director of Heidelberg Pharma and chief financial officer of Wilex, said, “This cooperation is an important external validation of our technology. We will use this cooperation to jointly explore and technically expand the applicability of our technology to selected antibodies.”

Dr. Klaus Bosslet, heading Roche discovery oncology in Germany, said, “We look forward to collaborating with Heidelberg Pharma to elect and develop the most promising ATACs. Ultimately, these ATACs may provide novel treatment options for cancer patients, whose tumors do not respond to available cancer therapeutics.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.